Clinical Trial Update: ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy

View source ↗

Summary

ODM 5, developed by TRB Chemedica AG, completed a clinical trial evaluating its use in treating corneal edema associated with Fuchs' Endothelial Dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Edema
• Fuchs Endothelial Dystrophy

Drugs mentioned

• ODM 5

Snippet

Sponsor: TRB Chemedica AG | Conditions: Fuchs' Endothelial Dystrophy, Corneal Edema | Status: COMPLETED